Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Femasys Inc
(NQ:
FEMY
)
1.330
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
235
Open
1.330
Bid (Size)
1.250 (11)
Ask (Size)
1.360 (1)
Prev. Close
1.330
Today's Range
1.330 - 1.330
52wk Range
0.2479 - 4.750
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
April 18, 2024
From
Femasys Inc.
Via
GlobeNewswire
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023
March 28, 2024
FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
+31.68%
+31.68%
1 Month
-17.39%
-17.39%
3 Month
+67.30%
+67.30%
6 Month
+7.26%
+7.26%
1 Year
+53.05%
+53.05%
More News
Read More
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
March 28, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
March 21, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
March 20, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
March 13, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
March 06, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
February 28, 2024
From
Femasys Inc.
Via
GlobeNewswire
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
February 21, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
February 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
February 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 07, 2024
Via
Benzinga
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
February 06, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
January 26, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
January 23, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
December 15, 2023
From
Femasys Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 14, 2023
Via
Benzinga
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
November 30, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
November 28, 2023
From
Femasys Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 24, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
November 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 22, 2023
Via
Benzinga
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
November 15, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
November 15, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
November 14, 2023
From
Femasys Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.